美國對進口藥品加徵新關稅
U.S. Imposes New Tariffs on Imported Pharmaceutical Drugs
2026年4月2日，美國政府推出一項大膽的新政策，旨在將藥品製造業遷回美國本土。
On April 2, 2026, the U.S. government introduced a bold new policy to shift pharmaceutical manufacturing back to American soil.
基於1962年《貿易擴張法》(ㄇㄠˋ ㄧˋ ㄎㄨㄛˋ ㄓㄤ ㄈㄚˇ)第232條的國家安全考量，政府宣布對進口藥品徵收高額關稅。
Citing national security concerns under Section 232 of the Trade Expansion Act, the administration announced significant tariffs on imported drugs.
品牌藥和專利藥將面臨100%的關稅，但企業若同意「最惠國待遇」(ㄗㄨㄟˋ ㄏㄨㄟˋ ㄍㄨㄛˊ ㄉㄞˋ ㄩˋ)定價或將生產設施遷移至美國，即可獲得豁免。
Branded and patented medications will face a 100% tariff, though companies can secure exemptions by agreeing to "Most Favored Nation" pricing or by relocating their production facilities to the United States.
雖然學名藥、生物相似藥及獸藥保持豁免，但該政策為製藥產業創造了複雜的環境。
While generic drugs, biosimilars, and veterinary medicines remain exempt, the policy creates a complex landscape for the pharmaceutical industry.
歐盟、日本和瑞士等戰略貿易夥伴享有較低的關稅上限，且英國也訂有特別協議。
Strategic trade partners like the European Union, Japan, and Switzerland benefit from lower tariff caps, and a special agreement is in place for the United Kingdom.
然而，該政策引發了辯論；批評者擔心小型生物科技公司可能在這些新的財政壓力下難以生存，擔憂監管規定偏袒資源豐富的大型企業。
However, the policy has sparked debate; critics worry that smaller biotech firms may struggle to survive under these new financial pressures, fearing that the regulations favor large, well-resourced corporations.
隨著120至180天的實施窗口開啟，製藥產業正迅速調整其製造策略，以應對這一不斷變化的監管環境。
As the 120 to 180-day implementation window opens, the industry is quickly adjusting its manufacturing strategies to navigate this evolving regulatory environment.
